WO2021038637A1 - Nouveau dérivé de vitamine a et son procédé de production - Google Patents

Nouveau dérivé de vitamine a et son procédé de production Download PDF

Info

Publication number
WO2021038637A1
WO2021038637A1 PCT/JP2019/033112 JP2019033112W WO2021038637A1 WO 2021038637 A1 WO2021038637 A1 WO 2021038637A1 JP 2019033112 W JP2019033112 W JP 2019033112W WO 2021038637 A1 WO2021038637 A1 WO 2021038637A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
formula
carbon atoms
salt
represented
Prior art date
Application number
PCT/JP2019/033112
Other languages
English (en)
Japanese (ja)
Inventor
坪井　誠
洋 岩▲崎▼
邦光 彼谷
昭盛 和田
由美子 山野
Original Assignee
リファインホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リファインホールディングス株式会社 filed Critical リファインホールディングス株式会社
Priority to PCT/JP2019/033112 priority Critical patent/WO2021038637A1/fr
Priority to JP2019559852A priority patent/JP6696060B1/ja
Publication of WO2021038637A1 publication Critical patent/WO2021038637A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/527—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings
    • C07C49/573—Unsaturated compounds containing keto groups bound to rings other than six-membered aromatic rings containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/297—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a novel vitamin A derivative and a method for producing the same.
  • Retinoids or vitamin A derivatives are used in various fields, especially in the fields of medicine, cosmetics and agricultural foods, and many synthetic methods are known. They bind to retinoid receptors in vivo and are used in the treatment of skin diseases such as acne, photoaging, and certain malignant tumors, and are also incorporated into cosmetics mainly for the purpose of beauty. Pharmaceuticals include tretinoin and adapalene, and cosmetics include retinol and retinol palmitate, which have been approved for the indication of wrinkle-improving action.
  • Tretinoin is an all-trans retinoic acid isomer (ATRA) in which all retinoic acid double bonds are trans-type.
  • ATRA all-trans retinoic acid isomer
  • This tretinoin is marketed as besanoid, which is a therapeutic agent for acute promyelocytic leukemia, and orsenone ointment, which is an external medicine suitable for pressure ulcers and skin ulcers (burn ulcer, diabetic ulcer, leg ulcer).
  • the promyelocytic leukemia cell line is a model cell line used for screening for apoptosis-inducing substances and differentiation-inducing substances.
  • the HL60 cell line is induced to differentiate, its proliferation is suppressed and the tumorigenic effect is lost by the final differentiation (decancerous state).
  • induction of apoptosis and induction of differentiation are considered as effective means, and certain anticancer agents and retinoic acid derivatives have already been clinically applied.
  • Tretinoin is said to have about 100 times the pharmacological action of retinol, but is known to have serious side effects such as teratogenicity and dyspnea.
  • retinoic acid and its analogs are vulnerable to ultraviolet rays and are unstable.
  • 7-hydroxyretinoic acid which has higher photostability than conventional retinoic acid and its derivatives, has been isolated from certain cyanobacteria (for example, Non-Patent Document 1 and Patent Documents). 1).
  • the amount of 7-hydroxyretinoic acid extracted from blue-green algae is extremely small, and it becomes a mixture of four isomers in the process of purifying this, so the carboxy group of 7-hydroxyretinoic acid is reduced. It is difficult to obtain 7-hydroxyretinol. Therefore, retinol having a hydroxy group or an oxo group at the 7-position or a derivative thereof is not yet known.
  • An object of the present invention is to provide a novel vitamin A derivative and a method for producing the same, which are useful as pharmaceuticals and cosmetics.
  • R 1 and R 2 are independent of each other, a hydrogen atom, an alkyl group having 1 to 12 carbon atoms, an alkenyl group having 2 to 10 carbon atoms, an alkynyl group having 2 to 10 carbon atoms, or 2 carbon atoms.
  • a compound represented by (30) acyl groups or a salt thereof is provided.
  • both R 1 and R 2 are hydrogen atoms.
  • R 1 is a hydrogen atom and R 2 is an acyl group represented by the formula (III): ⁇ CO (CH 2 ) n CH 3 (n is an integer of 0 to 28).
  • R 2 is an acetyl group, even more preferably.
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of the above or a salt thereof.
  • This pharmaceutical composition is used to treat night blindness, rickets, psoriasis, leukemia or dry eye inflammation, or to impart resistance to infection and promote body growth and bone and / or tooth development. It is preferable to do so.
  • a skin turnover promoter for preventing abnormal dryness and pigmentation of the skin which contains the compound described in any of the above or a salt thereof as an active ingredient. ..
  • the invention provides resistance to the treatment of night blindness, rickets, psoriasis, leukemia or dry eye inflammation, or imparts resistance to body growth and bone and / or tooth development.
  • a method comprising administering to a subject in need thereof an effective amount of any of the above compounds or salts thereof.
  • R 4 represents an alkyl group having 1 to 12 carbon atoms
  • R 5 represents an aryl group
  • X represents a halogen atom.
  • R 3 and R 4 represent alkyl groups having 1 to 12 carbon atoms independently of each other.
  • a method for producing a vitamin A derivative which comprises a step of obtaining a compound represented by.
  • a novel vitamin A derivative and a method for producing the same which are useful as pharmaceuticals and cosmetics, are provided.
  • FIG. 1 shows the quantification result of the NBT-positive cell rate using HL-60 cells for the compound of the present invention.
  • novel Vitamin A Derivative The novel vitamin A derivative according to the embodiment of the present invention is represented by the following formula (I): Or formula (II):
  • R 1 and R 2 are independent of each other, a hydrogen atom, an alkyl group having 1 to 12 carbon atoms, an alkenyl group having 2 to 10 carbon atoms, an alkynyl group having 2 to 10 carbon atoms, or 2 carbon atoms. It is a compound represented by (30) acyl groups or a salt thereof.
  • alkyl group having 1 to 12 carbon atoms means a monovalent linear or branched saturated hydrocarbon group consisting of only carbon atoms and hydrogen atoms and having 1 to 12 carbon atoms. ..
  • alkenyl group having 2 to 10 carbon atoms includes a linear or branched alkenyl group having 2 to 10 carbon atoms containing at least one double bond. Specifically, an ethenyl group, a propenyl group, a 1-methylethenyl group, a butenyl group, a 2-methylpropenyl group, a 1-methylpropenyl group, a pentenyl group, a 3-methylbutenyl group, a 2-methylbutenyl group, a 1-ethylpropenyl group, Hexenyl group, 4-methylpentenyl group, 3-methylpentenyl group, 2-methylpentenyl group, 1-methylpentenyl group, 3,3-dimethylbutenyl group, 1,2-dimethylbutenyl group, heptenyl group, 1- Examples thereof include a methylhexenyl group, a 1-ethylpentenyl group, an octenyl group, a 1-
  • alkynyl group having 2 to 10 carbon atoms includes a linear or branched alkynyl group having 2 to 10 carbon atoms containing at least one triple bond. Specifically, ethynyl group, propynyl group, butynyl group, pentynyl group, 3-methylbutynyl group, hexynyl group, 4-methylpentynyl group, 3-methylpentynyl group, 3,3-dimethylbutynyl group, heptynyl group. , Octinyl group, 3-methylheptinyl group, 3-ethylhexynyl group, noninyl group, or decynyl group.
  • an alkynyl group having 2 to 6 carbon atoms is mentioned, and more preferably, an alkynyl group having 2 to 4 carbon atoms is mentioned.
  • acyl group having 2 to 30 carbon atoms means the group R'-CO-, where R'is a linear or linear group having 1 to 29 carbon atoms which may have an unsaturated bond.
  • R' represents a branched alkyl group, an aryl group such as phenyl or naphthyl, or a heteroaryl group such as pyridyl, imidazolyl, thienyl, or frill containing a hetero atom selected from a nitrogen atom, a sulfur atom, and an oxygen atom as a ring member. ..
  • These groups may have a functional group such as an amino group.
  • acyl group having 2 to 30 carbon atoms include an acetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, a hexanoyl group, a lauroyl group, a palmitoyl group, and an oleoyl group. , Especially desirable to be an acetyl group.
  • a compound of formula (I) or formula (II) in which R is an acyl group having 2 to 30 carbon atoms can be synthesized by using a method already known for acylating a retinol compound. For example, 7-hydroxyretinol can be easily obtained by carrying out a monoacylation reaction with a lipase in the presence of an acylating agent (see JP-A-10-036301 and JP-A-2007-143561).
  • alkyl acylates and alkenyl acylates such as methyl acetate, ethyl acetate, butyl acetate, vinyl acetate, allyl acetate, isopropenyl acetate, ethyl propionate, ethyl butyrate and vinyl propionate and esters of long chain fatty acids such as Vinyl laurate can also be used as an acylating agent.
  • Ethyl acetate, butyl acetate or vinyl acetate is used for acetylation.
  • Vinyl esters of the corresponding fatty acids are also suitable for the production of long chain asherahs.
  • the amount of acylating agent used can be 1 molar equivalent or several times higher, but is particularly excessive when the acylating agent is used as a solvent at the same time, in the case of alkyl and alkenyl acylates. May be applicable.
  • the compound represented by the formula (I) or the formula (II) may be in the form of an isomer or a salt.
  • the acid addition salt include hydrochloride, hydrobromide, hydroiodide, sulfate, perchlorate, phosphate and other inorganic acid salts, oxalate, malonate, and succinic acid. Salt, maleate, fumarate, lactate, malate, citrate, tartrate, benzoate, trifluoroacetate, acetate, methanesulfonate, p-toluenesulfonate, trifluoromethane Examples include organic acid salts such as sulfonates.
  • the base salt include alkali metal salts such as sodium salt and potassium salt, and alkaline earth metal salts such as calcium salt.
  • isomer means a geometric isomer, an optical isomer or a tautomer.
  • the compounds of this embodiment include all of the above isomers and mixtures thereof in any proportion.
  • the novel vitamin A derivative of the present embodiment is photostable because the 7-position is hydroxyated or oxo-ized, so that the conjugated system of the conventional retinol and the retinol derivative is blocked. It is thought that the sex is improving. Furthermore, although not limited to a specific theory, the novel vitamin A derivative of the present embodiment may cause tautomerism and contribute to the improvement of photostability by always being present as a mixture.
  • R 4 represents an alkyl group having 1 to 12 carbon atoms
  • R 5 represents an aryl group
  • X represents a halogen atom.
  • R 3 and R 4 represent alkyl groups having 1 to 12 carbon atoms independently of each other.
  • R 4 represents an alkyl group having 1 to 12 carbon atoms.
  • the aldehyde represented by the formula (IV) can be synthesized by various methods. For example, as described in Scheme 1 and Examples described later, ⁇ -cyclocitral (1) is reacted with 4-bromo-3-methyl-2-butenenitrile (2) to produce hydroxynitrile (3). After synthesizing and protecting the hydroxy group at the 7-position with a silyl ether, the nitrile may be partially reduced to an aldehyde using diisobutylaluminum hydride.
  • Examples of the hydroxy group protecting group include a substituted silyl group (trimethylsilyl group, triethylsilyl group, tert-butyldimethylsilyl group, tert-butyldiphenylsilyl group, phenyldimethylsilyl group, etc.).
  • Examples thereof include tetrahydropyranyl group, tetrahydrofuranyl group, alkoxyalkyl group (methoxymethyl group, ethoxyethyl group, etc.), benzyloxymethyl group, benzyl group, trityl group, acyl group (formyl group, acetyl group, benzoyl group, etc.).
  • the reaction temperature is ⁇ 50 ° C. to room temperature, preferably ⁇ 30 ° C. to 0 ° C.
  • the Wittig reaction is a reaction of an aldehyde or ketone with a triphenylphosphonium ylide to give alkenes and triphenylphosphine oxides (A. Maercker, Org. React. 1965, 14, 270-490; A.W. Carruthers, Some Modern Methods of Organic Synthesis, Cambridge University Press, Cambridge UK1971, pp81-90).
  • the Wittig reaction is the most commonly used reaction for coupling aldehydes and ketones to phosphine ylides substituted alone.
  • Wittig reagent is usually prepared from a phosphonium salt, wherein the phosphonium salts are prepared by the reaction of Ph 3 P and a halogenated alkyl.
  • the Horner-Wadsworth-Emmons reaction (or HWE reaction) is a stabilized condensation reaction of a phosphonate carbanion with an aldehyde (or ketone) to predominantly produce an E-alkene.
  • Carbanions stabilized with phosphonates have higher nucleophilicity and higher basicity to the phosphonium ylide used in the Wittig reaction. These reactions can be carried out at a temperature in the range of usually ⁇ 78 to 60 ° C., preferably ⁇ 10 to 25 ° C. for usually 0.5 to 24 hours, preferably about 0.5 to 2 hours.
  • Suitable reducing agents include, but are not limited to , LiAlH 4 , LiBH 4 , NaBH 4-LiBr, and DIBAL.
  • the reducing agent is LiAlH 4 .
  • the reducing agent is LiBH 4 .
  • the reducing agent LiBH 4 may be produced in situ, for example by joint use of NaBH 4 and LiBr.
  • the amount of reducing agent is generally 0.8 to 1.6 equivalents, or more specifically 1.0 to 1.4 equivalents.
  • the obtained terminal alcohol may be acylated with a carboxylic acid anhydride.
  • the protecting group PG of the 7-position hydroxy group can be deprotected by a method known to those skilled in the art.
  • the protection of the hydroxy group by the substituted silyl group can be easily deprotected by using a fluorine anion or the like. it can.
  • reaction solvent if necessary, an inert organic solvent (for example, anhydrous tetrahydrofuran, anhydrous dimethyl sulfoxide, etc.) is used.
  • the reaction temperature is 0 to 50 ° C.
  • the product of each of the above steps can be separated and purified from the reaction mixture by a method known per se, for example, silica gel column chromatography, if necessary.
  • the compound represented by the above formula (II) is a keto-enol tautomer of 7-hydroxyretinol (I), both of which coexist in a solution at a predetermined abundance ratio, but are organic such as chloroform.
  • the proportion of ketoform represented by the formula (II) is high in the solvent.
  • Scheme 1 below shows one typical method for producing a compound of formula (II).
  • the starting material may be a known compound or may be prepared according to methods known in the art.
  • compositions and Therapeutic Uses The present invention relates to at least one compound described above, or an individual isomer, a racemic or non-racemic mixture of isomers, or a pharmaceutically acceptable salt or solvent thereof.
  • racemic mixture, psoriasis, leukemia or dry ophthalmitis, or containing Japanese products with at least one pharmaceutically acceptable carrier and optionally other therapeutic and / or prophylactic ingredients.
  • the pharmaceutical composition of this embodiment will be administered by any of the acceptable dosage forms for agents that contain therapeutically effective amounts of the above compounds and provide similar utility.
  • a therapeutically effective amount of a compound is related to the severity of the disease to be treated, the age and relative health of the subject, the efficacy of the compound used, the route and form of administration, the indication to which administration is directed, and. Depending on a number of factors such as physician preference and experience, it is typically 1 to 500 mg per day, preferably 1 to 100 mg per day, and most preferably 1 to 30 mg per day.
  • Those skilled in the art treating such diseases will be able to obtain therapeutically effective amounts of the compounds of the invention for a given disease without undue experimentation and, depending on personal knowledge and disclosure of the present application. You will be able to locate it.
  • the pharmaceutical composition of the present embodiment is oral (including buccal and sublingual), rectal, intranasal, topical, transpulmonary, transvaginal or parenteral (intramuscular, intraarterial, intrathecal, subcutaneous and venous). It may be administered as a pharmaceutical formulation containing those suitable for administration (including) or in a form suitable for administration by inhalation or aeration.
  • the preferred method of administration is generally oral using a convenient daily dosing regimen that can be adjusted according to the degree of distress.
  • the pharmaceutically acceptable carrier may be either solid or liquid.
  • Formulations in solid form include powders, tablets, pills, capsules, cashiers, suppositories and dispersible granules.
  • a solid carrier is one or more substances that can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrants, or encapsulating materials. You can.
  • the carrier is generally a micronized solid that is a mixture with a micronized active ingredient.
  • the active ingredient is generally mixed with a carrier having the required binding capacity in an appropriate proportion and shaped into the desired shape and size. Powders and tablets preferably contain from about 1 to about 70% of the active compound.
  • Suitable carriers include, but are not limited to, magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacant, methyl cellulose, sodium carboxymethyl cellulose, low melting point wax, cacao butter and the like.
  • formulation includes a formulation of an active compound having an encapsulating material as a carrier that provides a capsule in which the active ingredient with or without a carrier is surrounded by a carrier associated thereto. Intended.
  • cashiers and lozenges are included. Tablets, powders, capsules, pills, cashiers and lozenges can be in solid form suitable for oral administration.
  • Emulsions can be prepared in liquids, such as aqueous propylene glycol liquids, or can contain emulsifiers such as lecithin, sorbitan monooleate or acacia.
  • Aqueous solutions can be prepared by dissolving the active ingredient in water and adding the appropriate colorants, flavoring agents, stabilizers and thickeners.
  • Aqueous suspending agents can be prepared by dispersing the micronized active ingredient in water with viscous materials such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose and other well-known suspending agents. it can.
  • Solid form formulations include solutions, suspensions and emulsions, in addition to active ingredients, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizers. Etc. can be contained.
  • the pharmaceutical composition of the present embodiment can be formulated for parenteral administration (eg, by injection, eg, bolus injection or continuous infusion) and is a unit dose of ampoule, prefilled syringe, small volume infusion. It can also be provided in form or in a multi-dose container containing the added preservative.
  • the composition can take the form of a suspension, liquid or emulsion, such as a liquid of aqueous polyethylene glycol, in an oily or aqueous vehicle.
  • oily or non-aqueous carriers, diluents, solvents or vehicles examples include propylene glycol, polyethylene glycol, vegetable oils (eg olive oil), and organic esters for injection (eg ethyloleate), preservatives, wetting agents, etc. It may contain a compounding agent such as an emulsifier or suspending agent, a stabilizer and / or a dispersant.
  • the active ingredient is obtained by aseptic separation of the sterile solid or by lyophilization from the pre-use constitutive solution with a suitable vehicle, eg, sterile pyrogen-free water. It may be in powder form.
  • the pharmaceutical composition of the present embodiment can be formulated for topical administration to the epidermis as an ointment, cream or lotion, or as a transdermal patch.
  • ointments and creams can also be formulated with an aqueous or oily base with the addition of appropriate thickeners and / or gelling agents.
  • Lotions can be formulated with aqueous or oily bases and will generally also contain one or more emulsifiers, stabilizers, dispersants, suspending agents, thickeners or colorants.
  • Formulations suitable for topical oral administration are lozenges containing an active agent in a flavored base, usually sucrose and acacia or tragacanth; active in gelatin and glycerin or inactive bases such as sucrose and acacia.
  • novel vitamin A derivative described above can be used as a skin turnover accelerator for preventing abnormal dryness and pigmentation of the skin. Specifically, it is used for prevention and / or improvement of thinning or wrinkle formation of the epidermal viable cell layer, dryness, disordered texture, dullness, dark spots, darkening of spots, etc. due to delayed turnover. be able to.
  • a method for promoting epidermal turnover which comprises applying the above vitamin A derivative to the stratum corneum.
  • This method is for cosmetic purposes, not for the prevention or treatment of illness.
  • the subject of implementation may be a person other than a doctor, and specifically, a person who performs a beauty treatment for another person such as a cosmetics salesperson or an esthetician as a profession. It may also be the person to be treated.
  • the act of instructing and soliciting the person to be treated to implement the method of the present invention is also included in the implementation of the method of the present invention.
  • Whether or not the turnover of the epidermis is promoted can be evaluated by a known method.
  • a method of evaluating the turnover speed of the epidermis as a time change of the pigment of the epidermis can be mentioned.
  • the dye may be generated by patching an aqueous solution of DHA (dihydroxyacetone) on the medial side of the upper arm and labeling the skin in a tan color.
  • DHA dihydroxyacetone
  • it reacts with the amino acids that make the protein and the protein is altered, and this altered protein turns yellow or brown.
  • it can be evaluated by a method for evaluating epidermal turnover (see JP-A-2007-199053), which is characterized by using the presence position of a stratum corneum protein in the stratum corneum as an index.
  • the skin turnover accelerator in the present embodiment is the active ingredient of the vitamin A derivative, and further cosmetics such as diluents, stabilizers, antioxidants, preservatives, or external use on the skin. It may be the one to which an additive that is acceptable as an agent is added.
  • the skin turnover accelerator can be used as a component of cosmetics, external preparations for skin, and pharmaceutical compositions (hereinafter, referred to as "cosmetics and the like"). Cosmetics and the like can contain, for example, 0.00001 to 1% by mass or more of the above vitamin A derivative as a solid content, preferably 0.00001 to 0.1% by mass or more, and 0.0001 to 0.1. It is more preferable to contain by mass% or more.
  • Cosmetics and the like containing the above-mentioned vitamin A derivative can also be prepared in various dosage forms such as solid preparations, semi-solid preparations and liquid preparations, depending on the purpose of use. More specifically, cosmetics include cleansing, washing pigments, lotions, emulsions, creams, massage products, pack products, beauty liquids / gels, lip care products, etc. as basic cosmetics; foundations, face powders as base makeup cosmetics.
  • Makeup base concealer, etc .
  • As point makeup cosmetics lipstick, lip gloss liner, teak products, eye shadows, eye liners, mascara, eyebrow products, etc .
  • As cosmetics for hair or cosmetics for scalp shampoo, rinse, hair treatment, hair styling product, hair tonic, hair restorer, scalp treatment and the like can be used. Further, it can be a plaster, an ointment, a poultice, a liniment, a lotion, a coating agent, a patch, an aerosol agent (spray agent).
  • Cosmetics and the like containing the above-mentioned vitamin A derivative can contain various additives that are acceptable as cosmetics or pharmaceuticals, in addition to the agents of the present invention, as long as the effects of the present invention are not impaired. Examples of this are water (purified water, hot spring water, deep ocean water, etc.), surfactants (emulsifiers, solubilizers, suspending agents, stabilizers, etc.), antioxidants, preservatives, gelling agents, alcohols. Classes, film-forming agents, colorants, fragrances, deodorants, salts, pH adjusters, refreshing agents, chelating agents, keratolytic agents, enzymes, vitamins and the like.
  • the cosmetics and the like of the present embodiment can contain various functional ingredients that are acceptable as additives for cosmetics or external preparations for skin, as long as the effects of the skin turnover accelerator are not impaired.
  • ingredients are whitening agents, UV protection agents, antibacterial agents, anti-inflammatory agents, cell activators, reactive oxygen species removers, moisturizers, skin cleansing ingredients, acne and asemo-preventing ingredients.
  • Step 1 ⁇ Step of synthesizing hydroxynitrile (3) from ⁇ -cyclocitral (1)> An anhydrous tetrahydrofuran solution of ⁇ -cyclocitral (1) 1.63 g (10.7 mmol) and bromonitrile (2) 2.03 g (12.8 mmol) in 1.26 g (19.3 mmol) of activated zinc in a nitrogen stream. (20 mL) was added, and the mixture was reacted at room temperature for 3 and a half hours under ultrasonic irradiation. The reaction mixture was diluted with ethyl acetate and the insoluble material was filtered off with Celite.
  • Step 2 ⁇ Step of synthesizing siloxynitrile (4) from hydroxynitrile (3)>
  • anhydrous 6-chloromethane solution 10 mL
  • hydroxynitrile (3) 410 mg (1.76 mmol
  • 0.59 mL (3.5 mmol) of chlorotriethylsilane at 0 ° C. and reacting at room temperature for 16 hours, a saturated aqueous solution of ammonium chloride was added to stop the reaction.
  • Step 3 ⁇ Step of synthesizing siloxyaldehyde (5) from siloxynitrile (4)> 3.46 mL (3.46 mmol) of a 1.0 M hexane solution of diisobutylaluminum hydride in an anhydrous diethyl ether solution (50 mL) of 1.00 g (2.88 mmol) of silica gel (4) in a nitrogen stream at -30 ° C. In addition, after reacting at ⁇ 30 ° C. for 30 minutes, silica gel containing water was added to stop the reaction.
  • Step 4 ⁇ Step of synthesizing siloxyester (7) from siloxyaldehyde (5)> N-Butyllithium in anhydrous tetrahydrofuran solution (10 mL) of phosphonate (6) 0.99 mL (4.08 mmol) and N, N'-dimethylpropylene urea 1.48 mL (12.3 mmol) in a nitrogen stream at -30 ° C. 2.57 mL (4.08 mmol) of the 1.59 M hexane solution was added and reacted at ⁇ 30 ° C. for 15 minutes to prepare an anhydrous tetrahydrofuran solution containing the lithium salt of phosphonate (6).
  • Step 5 Step of synthesizing hydroxy ester (8) from siloxy ester (7)>
  • a nitrogen stream add 2.14 mL (2.14 mmol) of a 1.0 M tetrahydrofuran solution of tetra-n-butylammonium fluoride to an anhydrous tetrahydrofuran solution (10 mL) of 658 mg (1.43 mmol) of siloxyester (7) at 0 ° C.
  • a saturated aqueous solution of ammonium chloride was added to stop the reaction.
  • Step 6 ⁇ Step of synthesizing hydroxycarboxylic acid (9) from hydroxy ester (8)>
  • a 10% aqueous sodium hydroxide solution was added to an ethanol solution (11 mL) of 307 mg (0.89 mmol) of hydroxyester (8), reacted at 50 ° C. for 2 hours, and then saturated chloride.
  • Aqueous ammonium chloride was added to stop the reaction.
  • the organic matter was extracted with ethyl acetate, the organic layer was washed with saturated brine, dried, and the solvent was evaporated.
  • Step 7 ⁇ Step of synthesizing oxocarboxylic acid (10) from hydroxycarboxylic acid (9)>
  • a nitrogen stream add 410 mg (1.46 mmol) of 2-iodoxybenzoic acid in several portions to a mixed solution of 156 mg (0.49 mmol) of hydroxycarboxylic acid (9) in 3 mL of anhydrous tetrahydrofuran and 3 mL of anhydrous dimethyl sulfoxide at room temperature. After reacting at room temperature for 45 minutes, water was added to stop the reaction. The organic matter was extracted with ethyl acetate, the organic layer was washed with saturated brine, dried, and the solvent was evaporated.
  • Step 8 ⁇ Step of synthesizing hydroxyacetate (11) from siloxy ester (7)>
  • siloxyester (7) in anhydrous diethyl ether solution (5 mL) was added to 41 mg (1.06 mmol) of lithium aluminum hydride in anhydrous diethyl ether suspension (15 mL) at 0 ° C. After reacting at 0 ° C. for 10 minutes, water was added little by little to stop the reaction.
  • the crude product thus obtained was dissolved in anhydrous tetrahydrofuran mL, and 2.66 mL (2.66 mmol) of a 1.0 M tetrahydrofuran solution of tetra-n-butylammonium fluoride was added at room temperature in a nitrogen stream to 35. After reacting at ° C. for one and a half hours, a saturated aqueous solution of ammonium chloride was added to stop the reaction. The organic matter was extracted with ethyl acetate, the organic layer was washed with saturated brine, dried, and the solvent was evaporated.
  • Step 9 ⁇ Step of synthesizing oxoacetate (12) from hydroxyacetate (11)>
  • 2-iodoxybenzoic acid was added in several portions to a mixed solution of 320 mg (0.92 mmol) of hydrochiacetate (11) in 6 mL of anhydrous tetrahydrofuran and 3 mL of anhydrous dimethyl sulfoxide at room temperature.
  • water was added to stop the reaction.
  • the organic matter was extracted with ethyl acetate, the organic layer was washed with saturated brine, dried, and the solvent was evaporated.
  • Step 10 ⁇ Step of synthesizing diol (13) from siloxy ester (7)>
  • anhydrous diethyl ether suspension (15 mL) of 42 mg (1.11 mmol) of lithium aluminum hydride, 510 mg (1.11 mmol) of siloxyester (7) anhydrous diethyl ether solution (5 mL) was added at 0 ° C. After reacting at 0 ° C. for 10 minutes, water was added little by little to stop the reaction.
  • Step 11 ⁇ Step of synthesizing oxo alcohol (14) from diol (13)>
  • 0.17 mL (1.0 mmol) of chlorotriethylsilane was added to an anhydrous dichloromethane solution (8 mL) of 281 mg (0.92 mmol) of diol (13) and 0.39 mL (2.8 mmol) of triethylamine at 0 ° C.
  • water was added to stop the reaction.
  • the organic substance is extracted with ethyl acetate, the organic layer is washed with saturated brine, dried, and the solvent is distilled off.
  • the obtained residue is subjected to ethyl acetate / hexane (1/3 volume) using silica gel column chromatography. Ratio) Purification was performed using a mixed solvent as an elution solvent. 353 mg (0.84 mmol) of the resulting monosilyl ether was dissolved in 6 mL of anhydrous tetrahydrofuran and 3 mL of anhydrous dimethyl sulfoxide, and 472 mg (3.57 mmol) of 2-iodoxybenzoic acid was added in several portions in a nitrogen stream at room temperature. After reacting at room temperature for 30 minutes, water was added to stop the reaction.
  • leukemia cells have the ability to differentiate and are induced to differentiate into monocytes, granulocytes, erythrocytes, lymphocytes, etc. by the action of differentiation-inducing factors.
  • HL-60 cells are a cell line derived from acute promyelocytic leukemia, and when they differentiate into granulocytes (neutrophils) by the action of differentiation-inducing factors, their ability to generate active oxygen that reduces NBT (nitro blue terrazolium) increases. To do. Therefore, by investigating the NBT reducing ability, the effect of the compound of the present invention on the induction of differentiation of leukemia cells was investigated. The NBT reducing ability was measured by treating the cells with NBT to cause formazan precipitation and counting the cells stained in blue.
  • the compounds (12) and (14) produced in the above steps 9 and 11 are dissolved in ethanol and concentrated in ethanol at a predetermined concentration. Diluted to: This solution was added in an amount of 1/500 to the medium to prepare a medium containing a test substance having a concentration twice the target final concentration. As a solvent control, 1/500 amount of ethanol was added to the medium to prepare a double solvent control medium (final ethanol concentration 0.2%). These were prepared at the time of use.
  • HL-60 cells were awakened using medium and suspended cultured in a CO 2 incubator (37 ° C, 5% CO 2 , wet, and so on). Subcultured and expanded cultures were used for testing. Next, 50 ⁇ L of double test substance-added medium and double solvent-added medium were added to each well of the 96-well plate, and then HL-60 cells were seeded in each well at 2 ⁇ 10 4 cells / 50 ⁇ L, and 1 At a double solvent control concentration (EtOH final concentration 0.1%), the cells were cultured in a CO 2 incubator for 5 days and treated with the test substance. 100 ⁇ L of NBT solution and 2 ⁇ L of TPA solution were added to each well and incubated at 37 ° C. for 30 minutes.
  • the cells were then centrifuged at 1,200 rpm for 5 minutes and the cells were resuspended in 200 ⁇ L DPBS. Transfer 50 ⁇ L of the cell suspension to a new 96-well plate, centrifuge at 1,200 rpm for 1 minute, and then take a bright-field image of each well with KEYENCE BZ-X710 to count the total number of cells in the field and the number of NBT-positive cells. , NBT positive cell rate (number of NBT positive cells / total number of cells ⁇ 100) was calculated. Granulocytes were stained by NBT staining, and the NBT positive rate (granulocyte differentiation rate) was quantified.
  • the results are shown in Table 1 and FIG.
  • the NBT-positive cell rate of HL-60 cells was found to increase dose-dependently for each of the acetyl forms of 7-hydroxyretinol and 7-hydroxyretinol.
  • 7-hydroxyretinol and its derivatives according to the present invention have at least the ability to induce the differentiation of leukemia cells, they have the same physiological activity as retinol, and for example, night blindness, scab, psoriasis, leukemia or dryness. It can be used in pharmaceutical applications to treat ophthalmia or to impart resistance to infection and promote body growth and bone and / or tooth growth.
  • the 7-hydroxyretinol and its derivatives of the present invention have improved photostability as compared with retinol because the 7-position is hydroxy or oxo, and are suitable for use as cosmetics, especially as an external preparation for skin. Conceivable.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne : un nouveau dérivé de la vitamine A qui est utile en tant que médicament médicinal et produit cosmétique et qui comprend un composé représenté par la formule (I) ou la formule (II) (dans les formules, R1 et R2 représentent chacun indépendamment un atome d'hydrogène, un groupe alkyle ayant de 1 à 12 atomes de carbone, un groupe alcényle ayant de 2 à 10 atomes de carbone, un groupe alcynyle ayant de 2 à 10 atomes de carbone ou un groupe acyle ayant de 2 à 30 atomes de carbone), ou un sel de celui-ci ; et un procédé de production associé.
PCT/JP2019/033112 2019-08-23 2019-08-23 Nouveau dérivé de vitamine a et son procédé de production WO2021038637A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/JP2019/033112 WO2021038637A1 (fr) 2019-08-23 2019-08-23 Nouveau dérivé de vitamine a et son procédé de production
JP2019559852A JP6696060B1 (ja) 2019-08-23 2019-08-23 新規ビタミンａ誘導体およびその製造方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2019/033112 WO2021038637A1 (fr) 2019-08-23 2019-08-23 Nouveau dérivé de vitamine a et son procédé de production

Publications (1)

Publication Number Publication Date
WO2021038637A1 true WO2021038637A1 (fr) 2021-03-04

Family

ID=70682462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/033112 WO2021038637A1 (fr) 2019-08-23 2019-08-23 Nouveau dérivé de vitamine a et son procédé de production

Country Status (2)

Country Link
JP (1) JP6696060B1 (fr)
WO (1) WO2021038637A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011251942A (ja) * 2010-06-02 2011-12-15 Shinsangyo Sozo Kenkyusho:Kk ７位レチノイン酸誘導体
WO2018091937A1 (fr) * 2016-11-17 2018-05-24 University Of Debrecen Composés précurseurs pour obtenir des rétinoïdes de la voie de la vitamine a5 et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011251942A (ja) * 2010-06-02 2011-12-15 Shinsangyo Sozo Kenkyusho:Kk ７位レチノイン酸誘導体
WO2018091937A1 (fr) * 2016-11-17 2018-05-24 University Of Debrecen Composés précurseurs pour obtenir des rétinoïdes de la voie de la vitamine a5 et leurs utilisations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOSODA, A ET AL.: "Highly cis-selective Wittig reaction of oxido-allylic phosphorane with aldehyde. An efficient synthesis of 11-cis-retinoids", TETRAHEDRON LETTERS, vol. 28, no. 1, 1 January 1987 (1987-01-01), pages 65 - 68, XP055794587 *
KAYA, K ET AL.: "A novel retinoic acid analogue, 7- hydroxy retinoic acid, isolated from cyanobacteria", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1810, no. 4, 1 April 2011 (2011-04-01), pages 414 - 419, XP055794586 *

Also Published As

Publication number Publication date
JPWO2021038637A1 (ja) 2021-09-27
JP6696060B1 (ja) 2020-05-20

Similar Documents

Publication Publication Date Title
JP4563079B2 (ja) メントール誘導体及びそれを含有する冷感剤組成物
CA2752623C (fr) Composes alkylamides et leurs utilisations
FR3045604A1 (fr) Procede de depigmentation des matieres keratiniques a l'aide de composes thiopyridinones
JP5696738B2 (ja) 置換ベンジルエステル誘導体およびその用途
JPWO2017110317A1 (ja) ニコチンアミドモノヌクレオチド誘導体、その塩、その製造方法、皮膚外用剤、化粧料、食品添加剤
JPS62502471A (ja) レチノイド型作用を有する新規ナフタレン誘導体とその製造方法ならびにこれを含有する医薬および化粧品組成物
US8765809B2 (en) Ester derivative and use thereof
JP2006507287A (ja) 核内ホルモン受容体化合物、それを用いた製品及び方法
EP0989111A1 (fr) Nouveaux dérivés de l'acide 10-hydroxy-2-décénoique et utilisation dans une composition destinée à favoriser la desquamation de la peau, et composition le comprenant
WO2015186614A1 (fr) Nouveau composé et composition de parfum le contenant
EP2191816B1 (fr) Procédé de dépigmentation des matières kératiniques à l'aide de composés dithiolanes.
JP7073384B2 (ja) 化合物及び使用方法
WO2021038637A1 (fr) Nouveau dérivé de vitamine a et son procédé de production
CA2036846A1 (fr) Acylats d'acide lactique, leurs sels, leur procede de preparation et les compositions les renfermant
JP5994789B2 (ja) シワ防止化粧料
CN110121491A (zh) 3,4,5-三甲氧基肉桂酸酯衍生物、其制备方法以及含有该衍生物的皮肤美白组合物
US7396953B2 (en) Angiogenesis inhibitors and pharmaceutical/cosmetic applications thereof
JP7401426B2 (ja) 新規ラクトン化合物及び新規エーテル化合物
JP2826830B2 (ja) 新規ノルボルネン誘導体、その製造方法、それを含有する化粧用および薬学的組成物
JP7141025B1 (ja) 化合物、組成物、方法、及び製造方法
US10112890B2 (en) Compound, salt of compound, external agent for skin, cosmetic, and food additive
WO2011158333A1 (fr) Analogue de la zédérone et son procédé de synthèse
KR100332549B1 (ko) 스틸벤 유도체, 그의 제조방법 및 이를 유효성분으로함유하는 미백 화장료 조성물
JP2020045309A (ja) メントール誘導体塩及びその用途
JP2010132603A (ja) Ｖｅｇｆ産生促進剤

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2019559852

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19943384

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19943384

Country of ref document: EP

Kind code of ref document: A1